Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<jats:p>Despite promising progress in malaria vaccine development in recent years, an efficacious subunit vaccine against <jats:italic>P. falciparum</jats:italic> (Pf) remains to be licensed and deployed. Cell mediated protection from liver-stage malaria is reliant on a sufficient number of antigen specific T cells reaching the liver during the time that parasites are present. A single vaccine expressing two antigens could potentially increase both the size and breadth of antigen specific response, while halving vaccine production cost. In this study we investigated combining two liver stage antigens PfLSA1 and PfLSAP2, and investigated induction of protective efficacy by co-administration of single-antigen vectors or vaccination with dual-antigen vectors, using simian Adenovirus and Modified Vaccinia Ankara Virus vectors. Efficacy of these vaccines was assessed in mouse malaria challenge models using chimeric <jats:italic>P. berghei</jats:italic> parasites expressing the relevant Pf antigens and challenging mice at the peak of T cell response. Vaccination with a combination of the single-antigen vectors expressing PfLSA1 or PfLSAP2 was shown to improve protective efficacy compared to vaccination with each single antigen vector alone. Vaccination with dual-antigen vectors expressing both PfLSA1 and PfLSAP2 resulted in responses to both antigens, particularly in outbred mice, and most importantly efficacy was equivalent to vaccination with a mixture of single-antigen vectors. Based on this promising data, dual-antigen vectors expressing PfLSA1 and PfLSAP2 will now proceed to GMP manufacturing and clinical assessment.</jats:p>

Original publication




Journal article


Infection and Immunity


American Society for Microbiology

Publication Date